Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 10 (October)

1. Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging.
   Int J Radiat Oncol Biol Phys, 63(3): 800-11. [Abstract] [Full-text]
2. Long-term androgen deprivation therapy improves survival in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/mL.
   Int J Radiat Oncol Biol Phys, 63(3): 781-7. [Abstract] [Full-text]
3. High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer.
   Genes Chromosomes Cancer, 44(4): 438-49. [Abstract] [Full-text]
4. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10).
   Int J Radiat Oncol Biol Phys, 63(3): 788-94. [Abstract] [Full-text]
5. Amplification and overexpression of prosaposin in prostate cancer.
   Genes Chromosomes Cancer, 44(4): 351-64. [Abstract] [Full-text]
6. The human Y chromosome suppresses the tumorigenicity of PC-3, a human prostate cancer cell line, in athymic nude mice.
   Genes Chromosomes Cancer, 44(4): 365-72. [Abstract] [Full-text]
7. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry.
   Int J Radiat Oncol Biol Phys, 63(3): 772-80. [Abstract] [Full-text]
8. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
   Int J Radiat Oncol Biol Phys, 63(3): 795-9. [Abstract] [Full-text]
9. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy.
   Int J Radiat Oncol Biol Phys, 63(3): 765-71. [Abstract] [Full-text]
10. p63/AMACR antibody cocktail restaining of prostate needle biopsy tissues after transfer to charged slides: a viable approach in the diagnosis of small atypical foci that are lost on block sectioning.
    Am J Clin Pathol, 124(5): 708-15. [Abstract] [Full-text]
11. Prostatic stromal sarcoma in a young adult: a case report.
    Arch Androl, 51(6): 419-24. [Abstract] [Full-text]
12. Over-expression of CD9 does not affect in vivo tumorigenic or metastatic properties of human prostate cancer cells.
    Biochem Biophys Res Commun, 337(2): 498-504. [Abstract] [Full-text]
13. Lidocaine suppositories for prostate biopsy.
    BJU Int, 96(7): 1028-30. [Abstract] [Full-text]
14. The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.
    BJU Int, 96(7): 1014-8. [Abstract] [Full-text]
15. Salvage radiotherapy for biochemical recurrence after radical prostatectomy.
    BJU Int, 96(7): 1009-13. [Abstract] [Full-text]
16. Intra-operative prostate examination: predictive value and effect on margin status.
    BJU Int, 96(7): 1005-8. [Abstract] [Full-text]
17. Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy.
    BJU Int, 96(7): 999-1004. [Abstract] [Full-text]
18. The effect of percentage free prostate-specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low PSA levels.
    BJU Int, 96(7): 995-8. [Abstract] [Full-text]
19. A retrospective study of the time to clinical endpoints for advanced prostate cancer.
    BJU Int, 96(7): 985-9. [Abstract] [Full-text]
20. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
    BJU Int, 96(7): 964-9. [Abstract] [Full-text]
21. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.
    J Orthop Res, 23(6): 1475-83. [Abstract] [Full-text]
22. Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer.
    Int J Cancer, 117(5): 738-45. [Abstract] [Full-text]
23. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity.
    J Natl Cancer Inst, 97(20): 1525-32. [Abstract] [Full-text]
24. Androgen receptor binding sites identified by a GREF_GATA model.
    J Mol Biol, 353(4): 763-71. [Abstract] [Full-text]
25. Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells.
    Carcinogenesis, 26(11): 1896-904. [Abstract] [Full-text]
26. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers.
    Radiology, 237(2): 541-9. [Abstract] [Full-text]
27. Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies.
    Cancer, 104(9): 1911-7. [Abstract] [Full-text]
28. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study.
    Br J Cancer, 93(9): 1019-23. [Abstract] [Full-text]
29. Diet, vegetarian food and prostate carcinoma among men in Taiwan.
    Br J Cancer, 93(9): 1057-61. [Abstract] [Full-text]
30. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer.
    Int J Cancer, 117(6): 1039-48. [Abstract] [Full-text]
31. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
    Science, 310(5748): 644-8. [Abstract] [Full-text]
32. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy.
    J Clin Oncol, 23(31): 7904-10. [Abstract] [Full-text]
33. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.
    J Clin Oncol, 23(31): 7897-903. [Abstract] [Full-text]
34. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
    Lancet Oncol, 6(11): 841-50. [Abstract] [Full-text]
35. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study.
    Lancet, 366(9496): 1554-7. [Abstract] [Full-text]
36. Geographic and socioeconomic variation in the treatment of prostate cancer.
    J Clin Oncol, 23(31): 7881-8. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.